Phase I study of S-1 and nedaplatin for patients with recurrence of head and neck cancer.

Autor:	Kodaira T; Department of Therapeutic Radiation Oncology, Aichi Cancer Center Hospital, 464-8681 Nagoya, Aichi, Japan. 109103@aichi-cc.jp, Fuwa N, Tachibana H, Hidano S
Jazyk:	angličtina
Zdroj:	Anticancer research [Anticancer Res] 2006 May-Jun; Vol. 26 (3B), pp. 2265-8.
Abstrakt:	Unlabelled: A phase I study of chemotherapy was planned with S-1 and nedaplatin to find the optimal dose for patients with recurrent head and neck cancer. Materials and Methods: Oral administration of S-1 (days 1-14) and intravenous nedaplatin (day 8) were tested for patients with recurrent head and neck cancer in a phase-I setting. The dose of S-1 was fixed and the dose of nedaplatin was escalated from 80 mg/m2, with an increase of 10 mg/m2 per step, to find the maximum tolerated dose. Results: Nine patients were recruited in this trial. The maximum tolerated dose (MTD) of nedaplatin was 90 mg/m2. At this dose level, dose-limiting toxicity (DLT) was observed in two out of three patients. One experienced grade 4 thrombocytopenia and febrile grade 3 neutropenia, while the other suffered myelosuppression causing more than a two-week delay of the second chemotherapy cycle. Myelosuppression was the DLT of this regimen. Conclusion: The recommended phase II dose of nedaplatin combined with oral S-1 was identified as 80 mg/m2.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu